Downregulating testosterone levels enhance immunotherapy efficiency

Low response rates to certain tumor types remain a major challenge for immune checkpoint blockade therapy. In this study, we first conducted an integrated biomarker evaluation of bladder cancer patients from confirmatory cohorts (IMvigor210) and found that no significant differences exist between se...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Luoyang, Jiang, Guoqiang, Jing, Nan, Liu, Xuerun, Zhuang, Huiren, Zeng, Wenfeng, Liang, Wei, Liu, Zheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477942/
https://www.ncbi.nlm.nih.gov/pubmed/34595060
http://dx.doi.org/10.1080/2162402X.2021.1981570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477942/
https://www.ncbi.nlm.nih.gov/pubmed/34595060
http://dx.doi.org/10.1080/2162402X.2021.1981570

Ejemplares similares